Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Laryngoscope. 2010 Feb;120(2):432-5. doi: 10.1002/lary.20757.

Hereditary hemorrhagic telangiectasia/avastin.

Author information

  • 1Department of Head and Neck Surgery, San Diego School of Medicine, University of California, VA San Diego Healthcare System, San Diego, California 92161, USA. tdavidson@ucsd.edu

Abstract

This is the first scientific report of hereditary hemorrhagic telangiectasia (HHT) epistaxis treatment by intranasal spraying of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin). Epistaxis in patients with HHT is a morbid, mortal condition that is difficult and unpleasant to manage. Nasal telangiectasia growth is modulated by VEGF, which is elevated in HHT patients. Bevacizumab is a VEGF inhibitor that diminishes epistaxis when administered intravenously or injected locally, or as reported here when sprayed topically onto the nasal mucosa.

Comment in

PMID:
19998344
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk